Bank of Montreal Can Purchases 20,799 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Bank of Montreal Can grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 9.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 245,711 shares of the medical research company’s stock after acquiring an additional 20,799 shares during the quarter. Bank of Montreal Can’s holdings in IQVIA were worth $51,968,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of IQV. Rise Advisors LLC acquired a new stake in IQVIA during the first quarter worth $31,000. Versant Capital Management Inc lifted its holdings in shares of IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after acquiring an additional 110 shares during the period. Riverview Trust Co acquired a new stake in shares of IQVIA during the 1st quarter valued at about $32,000. Opal Wealth Advisors LLC bought a new stake in IQVIA in the second quarter valued at about $27,000. Finally, Itau Unibanco Holding S.A. acquired a new position in IQVIA in the second quarter worth about $29,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Price Performance

Shares of IQV stock opened at $231.71 on Thursday. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The firm has a market cap of $42.24 billion, a price-to-earnings ratio of 31.65, a PEG ratio of 2.26 and a beta of 1.49. The stock has a 50-day moving average price of $241.03 and a 200 day moving average price of $233.69.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. During the same period in the previous year, the firm posted $2.22 earnings per share. IQVIA’s revenue for the quarter was up 2.3% compared to the same quarter last year. Research analysts expect that IQVIA Holdings Inc. will post 10.25 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Evercore ISI upped their price objective on IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a research note on Tuesday, July 23rd. Robert W. Baird lifted their price objective on IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a report on Friday, September 20th. Truist Financial upped their target price on shares of IQVIA from $292.00 to $300.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Barclays lifted their price target on shares of IQVIA from $255.00 to $275.00 and gave the company an “overweight” rating in a report on Tuesday, July 23rd. Finally, Morgan Stanley upped their price objective on shares of IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 23rd. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average price target of $267.00.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.60% of the stock is owned by corporate insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.